Incyte (INCY) on Monday posted a Phase 3 trial win for tafasitamab, an antibody therapy it has developed with Xencor (XNCR), setting up a potential label expansion for the drug as a first-line option ...

Aktis Oncology (AKTS), a radiopharmaceutical drug developer that counts Eli Lilly (LLY) among its partners, filed SEC filings on Monday for its U.S. initial public offering, which could value it at up ...

New year. Fresh start. Moving on. Right? Not so much for most of the thousands of people displaced a year ago by the twin fire calamities that hit the east and west ends of Los Angeles County. The ...

2025 wasn’t a one-sound year; it was a many-voices year in Hip-Hop albums, where street rap, art rap, introspection and legacy all shared the same space. This was the year Hip-Hop slowed down and ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Accelerant ...